Enzon Pharmaceuticals (OTCMKTS:ENZN) Shares Down 2.6%
Enzon Pharmaceuticals Inc (OTCMKTS:ENZN) shares dropped 2.6% on Monday . The company traded as low as $0.22 and last traded at $0.24. Approximately 7,600 shares traded hands during trading, a decline of 75% from the average daily volume of 30,743 shares. The stock had previously closed at $0.25.
The firm’s fifty day simple moving average is $0.23.
Enzon Pharmaceuticals Company Profile (OTCMKTS:ENZN)
Enzon Pharmaceuticals, Inc, together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron for use in the treatment of chronic hepatitis C; and Sylatron for use in the treatment of melanoma disease. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
Receive News & Ratings for Enzon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.